Preoperative lnterleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients

Oncology (Switzerland)

Volumn 53, Issue 4, 1996, Pages 263-268

  Brivio, Fernando ^a   Lissoni, Paolo ^a   Alderi, Giovanni ^a   Barni, Sandro ^a   Lavorato, Francesco ^a   Fumagalli, Luca ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b Chiron Company   (Italy)

Author keywords

Immunosuppression; Immunotherapy; Interleukin 2

Indexed keywords

FLUOROURACIL; FOLIC ACID; RECOMBINANT INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; T LYMPHOCYTE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PALLIATIVE CARE; SURVIVAL RATE; T-LYMPHOCYTES; TIME FACTORS;

EID: 0029901462     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227571     Document Type: Article

References (12)

1. Bancewiez J, Aileen CG, Lindop G: The immunosuppressive effect of surgery. Br J Surg 1973; 60:314-318.
2. Uchida A, Kolb R, Micksche M: Generation of suppressor cells for natural killer activity in cancer patients after surgery. J Natl Cancer Inst 1982;68:735-739.
3. Eggermont AMM, Steller EP, Sugarbaker PH: Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effect of intcrleukin-2 and lymphokine activated killer cells. Surgery 1987;102:71-78.
4. Fong Y, Moldawer LL, Dhires GY, Lowry SF: The biological characteristics of cytokines and their implication in surgical injury. Surg Gynecol Obstet 1990;170:363-378.
5. Lazarou SA, Barbul A, Wasserkrug HL, Efron G: The wound is a possible source of posttrau-matic immunosuppression. Arch Surg 1989; 124:1429-1431.
6. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokinc-activatcd killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982:155:1823-1841.
7. Brivio F, Lissoni P, Tisi E, Erba L, Bami S, Tancini G, Rescaldani R, Alderi G, Nociti V: Effects of a preoperative therapy with interleu-kin-2 on surgery-induced lymphocytopenia in cancer patients. Oncology 1992:49:215-218.
8. Nichols PH, Ramsden CW, Ward U, Sedman PC, Primrose JN: Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res 1992:52:5765-5769.
9. Mule JJ, Shu S, Rosenberg SA: The antitumor efficacy of lymphokine-activatcd killer cells and recombinant intcrleukin-2 in vivo. J Immunol 1985;135:646-650.
10. Atzpodien J, Kirchner H: Cancer, cytokines, and cytotoxic cells: Intcrleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 1990;68:1-11.
11. Pretlow TP, Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow TG, Kimball PM, Boo-haker EA: Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 1983:43:2997-3000.
12. Cohen PJ, Lotzc MT, Roberts JR. Rosenberg SA, Jaffe ES: The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol 1987:129:208.